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Objective: To evaluate BRAFV600E mutation on consecutive fine-needle aspiration biopsy (FNAB) specimens in
order to assess FNAB’s usefulness in preoperative papillary thyroid carcinoma (PTC) diagnosis with the con-
temporaneous analysis of RET=PTC1 and RET=PTC3 rearrangements obtained from ex vivo thyroid nodules.
Design: Thyroid FNABs from 156 subjects with nodules and 49 corresponding surgical samples were examined
for the presence of BRAF mutation by real-time allele-specific polymerase chain reaction, confirmed with the use
of a laser pressure catapulting system. Samples were also examined for RET=PTC rearrangements. The results
were compared with the cytological diagnosis and histopathology. Main outcomes: 13=156 cytological exami-
nations were diagnostic for PTC and 19=156 showed suspicious=indeterminate FNAB (12.2%). FNAB-BRAFV600E
mutation was detected in 11=16 (69%) cases with histological confirmation of PTC. In our series, RET=PTC
rearrangement was detected in only one case of PTC, whereas it was not present in any case of adenoma, goiter,
or Hashimoto’s thyroiditis. No PTC case was found positive at the same time for BRAF mutation and RET=PTC
rearrangements. Conclusion: BRAFV600E mutation detected on FNAB specimens, more than RET=PTC rearrange-
rangements, is highly specific for PTC and its routine research might well be an adjunctive and integrative diag-
nostic tool for the preoperative diagnostic iter.
Introduction
Thyroid cancer harbors several genetic alterations,some of which have been described only in papillary
thyroid carcinomas (PTCs). The classical oncogenic genetic
alterations commonly seen in PTC include RET=PTC rear-
rangements (1–3). Among at least 10 types of RET=PTC rear-
rangementsdescribed,RET=PTC1,RET=PTC2,andRET=PTC3
are the most common and occur mainly in PTC and some
benign adenomas, generally prevalent in pediatric popula-
tions and in patients exposed to radiation. More recently, an
activating mutation in BRAF (the gene for the B-type Raf
kinase, BRAF) has been described and represents the most
common genetic alteration in PTC. BRAF is the most potent
activator of the mitogen-activated protein kinase (MAP ki-
nase) pathway (4,5). The most frequent BRAF mutation is
designated T1799A (6), resulting in a V600E (formerly desig-
nated V599E) amino acid substitution in the protein product
and subsequent constitutive activation of the BRAF kinase
(7–10), which accounts for the oncogenic and transforming
function (7). Since their initial identification, BRAF mutations
have subsequently been reported in numerous types of hu-
man cancer with various frequencies (11), such as melano-
mas and nevi (7,12). More recently, numerous studies have
consistently shown a high prevalence of BRAF mutation in
thyroid cancer, ranging from 29 to 83% (13–15).
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In PTC, RET=PTC rearrangements and BRAFmutation have
been commonly identified, causing tumorigenesis through the
Ras?Raf?MAP kinase (16,17). Fine-needle aspiration biopsy
(FNAB) with cytological analysis is widely used and has be-
come the principal tool in thyroid nodule evaluation (18). The
aim of the present study was to detect BRAF mutation in cy-
tological specimens from FNAB thyroid nodules and to assess
FNAB usefulness in improving the diagnostic accuracy in the
identification of PTC patients. Moreover, we evaluated RET=
PTC1 and RET=PTC3 rearrangements in ex vivo thyroid nod-
ules for a more complete molecular analysis in PTC.
Materials and Methods
Patients, high-resolution ultrasonography,
and FNAB procedures
This study was performed in accordance with the rules of
the Institutional Review Board at the Faculty of Medicine,
University of Palermo.
We recruited 156 subjects (36 males and 120 females; age:
49.63 14.29 years, range: 21–83 years) from the cohort of
patients affected by thyroid nodules followed up in our out-
patient clinic during September 2005 to June 2006. Because
their high-resolution ultrasonography (US) features were sus-
picious for increased malignancy risk (hypoechoic nodules
$10mm with irregular margins, intranodular vascular spots,
a taller-than-wider shape, or microcalcifications, grade B)
(19), patients underwent FNAB (US-guided FNAB) after their
informed consent also for the molecular genetic analysis.
Briefly, three to four aspirations with a 25- to 27-gauge needle
were typically made in order to harvest material for cytolog-
ical and molecular analyses. FNAB smears were stained with
May Grumwald Giemsa or Papanicolau, and were considered
diagnostic for PTC when they fulfilled the six diagnostic cri-
teria required (20,21). FNAB smears were considered suspi-
cious=indeterminate when they showed only some (from three
to five) of the six diagnostic features. All samples that were
defined insufficient (i.e., not enough thyroid cells for diagno-
sis; less than six clusters of cells) underwent a further FNAB.
The schematic map of FNA-biopsied nodule=nodules was
recorded and assisted the pathologist in the final identifica-
tion and sampling of the thyroid nodule.
Material for molecular analysis was washed in normal
saline in a 50-mL plastic tube. After centrifugation, the pellet
was resuspended and washed twice in phosphate buffer so-
lution (PBS), and then stored at  208C until use.
Histology
After surgical resection, thyroid glands were examined by
the on-call pathologist in order to identify the FNAB-treated
nodule and to obtain a small tissue sample for RNA extrac-
tion (see RNA extraction from ex vivo thyroid nodules) whilst
the remaining tissue was fixed in 10% neutral buffered for-
malin and embedded in paraffin blocks. Sections (4-mm thick)
were stained with hematoxylin–eosin for histological exami-
nation. The nuclear and architectural features were carefully
evaluated for final histological diagnosis (20).
Clinicopathological data including size of tumor, extra-
thyroid invasion, node metastasis, associated thyroid lesions,
and metastatic deposits were recorded according to the VI
edition of the TNM classification (22).
Detection of BRAFV600E mutation
DNA was extracted from FNAB pellets using a Qiagen
DNAeasy Tissue Kit according to the manufacturer’s proto-
col (Qiagen, Hilden, Germany). BRAFV600E mutation was
detected by real-time allele-specific amplification essentially
as described by Jarry et al. (23). Amplification was performed
with a Lightcycler (Roche Diagnostics GmbH, Mannheim,
Germany), and fluorescence was measured within the F1
channel. After completion of the cycling process, samples
were subjected to melting curve analysis. Briefly, samples
were slowly cooled down (0.18C=s) to 508C for 30 s and then
to a temperature ramp from 508C to 908C at 0.18C=s with
continuous fluorescence monitoring. For each sample, the
dF1=dT versus temperature (T) plot was displayed, and a
single narrow peak was obtained, indicating specific ampli-
fication without significant by-products. Positive results were
further confirmed using a B-RAF Mutector Single-Well Test
Kit (Trimgen, Tebu-Bio, Milan, Italy), following the manu-
facturer’s instructions. Cases in which the genotype ratio
(absorbance from sample=absorbance from wild type) was
$2 were interpreted as mutant (24). ARO cell DNA was used
as a positive control.
Laser pressure catapulting system
In all cases histologically diagnosed as PTC, in order to
avoid cell heterogeneity, which may affect the assessment of
the mutational status of BRAF V600E, all resection specimens
and microscopic slides were meticulously examined by two
independent pathologists who were unaware of the original
diagnosis and of the results of the molecular analysis (Vito
Rodolico and Daniela Cabibi). Tissue sections, prepared with
a microtome and placed on a slide, were processed for the
laser pressure catapulting (LPC) microdissection through a
Zeiss inverted microscope PALM laser Micro-Beam System
(Carl Zeiss AG, Oberkochen, Germany), linked to a PC with
the required software programs, as previously described (25).
Genomic DNA was extracted using the QIAamp Tissue Kit
(Qiagen, Hilden, Germany) with the standard protocol, and
BRAF mutation detected as above described.
RNA extraction from ex vivo thyroid nodules
After surgical resection, thyroid samples from nodules ob-
tained by means of careful identification by an experienced
pathologist and corresponding to the biopsied nodule were
quickly stored in RNA later (Sigma, Milan, Italy) and stored
at  208C until use. Samples were further processed with the
RNAEasy Mini Kit (Qiagen, Milan, Italy) for RNA extraction,
following the manufacturer’s instructions.
Detection of RET=PTC rearrangements by RT-PCR
Detection of RET=PTC1 and RET=PTC3 involved conven-
tional two-step RT-PCR followed by agarose gel electropho-
resis. Briefly, 2mg of total RNA was reverse transcribed in a
volume of 20 mL with random hexamer primers and Super-
script II RT (Invitrogen, Milan, Italy) according to the man-
ufacturer’s protocol. Two microliters of cDNA samples was
analyzed for RET=PTC1 and RET=PTC3 using 35 cycles of
PCR amplification as previously reported (26). All samples
were assessed for the adequacy of RNA by amplification of
the beta-actin housekeeping gene and for the RET tyrosine-
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kinase domain. The PCR products were electrophoresed
on a 1.5% agarose gel and visualized by ethidium bromide
staining.
BRAF mutation in peripheral blood lymphocytes
from surgically treated patients
Peripheral blood lymphocytes from recruited subjects were
isolated by Ficoll Hypaque gradients using standard proce-
dures, and DNA was extracted by Qiagen DNAeasy Tissue
Kit according to the manufacturer’s protocol.
Statistical methods
Categorical data were described as rates and proportions.
The age of the patients was expressed as mean standard
deviation (SD). Differences in BRAF-mutated cases for his-
tological data were calculated by Fisher test. The value of
p< 0.05 was considered statistically significant. Data were an-
alyzed using SPSS V.13 for Windows software (Milan, Italy).
Results
FNAB cytological data in relation to BRAF mutation
Onehundredandfifty-six consecutivepatientswith thyroid
nodules underwent US-FNAB. Forty-nine patients out of 156
(31.4%) with biopsied nodules underwent total or near-total
thyroidectomy following cytological findings or for compres-
sive symptoms, trachea dislocation, and=or esthetical reasons,
differently combined for each patient.
BRAF mutation from FNAB-extracted samples was de-
tected in 11 out of 49 (22.4%) patients undergoing surgery. In
the remaining 107 nonsurgically treated patients, we did not
find any BRAFV600E mutation. All positive samples were
confirmed by a colorimetric assay. Cytological findings were
conclusive for PTC in 13 and suspicious=indeterminate in 19
(12.2%) out of 156 patients studied. With regard to BRAF mu-
tation, FNAB cytological analyses were diagnostic for PTC in
9=11 cases, while 2=11 sampleswere foundwithin suspicious=
indeterminate results (Table 1). Four samples were diagnostic
for PTC by cytology but negative for BRAF mutation. Among
19 cases with suspicious=indeterminate FNAB, 3 cases were
PTC, 1 follicular thyroid cancer (FTC), 1 Hashimoto’s thy-
roiditis (HT), 12 goiters, and 2 adenomas, as demonstrated
by histology (see Histological data in relation to BRAF mu-
tation). Among the latter suspicious=indeterminate FNAB
findings, BRAF mutation was found exclusively in two out of
three PTC cases, one conventional variant (CV) and one
follicular variant (FV). In the remaining specimens involving
benign thyroid diseases, no case with BRAF positivity and
FNAB negativity was found, confirming the high specificity
of BRAF mutation in PTC cytological specimens.
None of the 156 surgically treated or untreated patients
showed a somatic mutation of BRAF in peripheral blood
lymphocytes.
Histological data in relation to BRAF mutation
Among 49 patients who underwent thyroidectomy, 16
cases with PTC variants (CV¼ 11; FV¼ 2; tall-cell¼ 3), 1 FTC,
4 adenomas (Hurthle¼ 1; microfollicular¼ 2; microfollicular=
macrofollicular¼ 1), 26 large benign goiters, and 2 HT were
histologically diagnosed (Table 1).
Eleven out of 16 PTC (69%) harbored BRAF mutation as
detected in DNA extracted by both US-FNAB nodules and
LPC. The highest prevalence of BRAFV600E mutations was
found in 8=11 classic PTC (72%), whereas FV PTC had a lower
prevalence (one out of two). However, it was not possible to
draw statistically valid conclusions from the histological re-
sults because of the limited number of samples examined.
Table 1. Molecular Analysis of Thyroid Histology
and FNAB in 49 Patients Undergoing Thyroidectomy
BRAFV600E
positivity
RET=PTC
rearrangement
Histology (No. of cases) No. of cases (%) No. of cases (%)
Papillary carcinoma (16) 11 (69) 1 (6) (1 PTC3)
Classic variant (11) 8 (72) –
Follicular variant (2) 1 (50) 1 (50)
Tall-cell variant (3) 2 (67) –
Follicular carcinoma (1) – –
Adenoma (4) – –
Microfollicular (2) – –
Micro=macrofollicular (1) – –
Hurthle (1) – –
Multinodular goiter (26) – –
Hashimoto’s thyroiditis (2) – –
Cytology (No. of cases) No. of cases (%) No. of cases (%)
Diagnostic FNAB (30) 9 (30) –
PTC (13) 9 (69) –
Goiter (14) – –
Hashimoto’s
thyroiditis (1)
– –
Adenoma (2) – –
Suspicious=indeterminate
FNAB (19)
2 (10.5)
Papillary carcinoma
(CV) (2)
1 (50) –
Papillary carcinoma
(FV) (1)
1 (100) –
Follicular carcinoma
(FTC) (1)
– –
Goiter (12) – –
Adenoma (2) – –
Hashimoto’s
thyroiditis (1)
– –
Tumor stage of 16 PTC No. of cases (%) No. of cases (%)
T1 (13) 9 (69) 1 (7.7)
T2 (2) 1 (50) –
T4 (1) 1 (100) –
Gender of 16 PTC
Male (6) 5 (83) 1 (16.7)
Female (10) 6 (60) –
Age of 16 PTC
#40 years (12) 8 (67) 1 (8)
>40 years (4) 3 (75) –
Node metastasis (PTC)
Yes (3) 2 (67) –
No (13) 9 (69) –
Data are presented as no.=total no. of patients, with percentages in
parentheses. FNAB: fine-needle aspiration biopsy; PTC: papillary thy-
roid carcinoma; CV: conventional variant; FV: follicular variant; FTC:
follicular thyroid cancer.
BRAF AND RET=PTC IN PAPILLARY THYROID CARCINOMA 1111
We found that there was a strict concordance between
BRAF mutation status and the final cytological=histological
diagnosis of PTC.
A representative example of BRAFV600E mutation and
cytological and histological findings in one case of PTC is
shown in Figure 1.
BRAF mutation in relation to tumor stage,
gender, age, and lymph node
metastases in 16 PTCs
BRAF mutation was found in 9 out of 13 T1 cases (69%), 1
out of 2 T2 cases (50%), and 1 out of 1 T4 case (100%) of PTC
examined. As regards sex and age, BRAF mutation was de-
tected in 5=6 (83%) of males in comparison to 6=10 (60%) of
females as well as in 8=12 (67%) and in 3=4 (75%) of patients
under and over 40 years, respectively. With regard to lymph
node (LN) status, BRAF mutation was detected in 2=3 cases
with LN metastases (Table 1).
RET=PTC1 and RET=PTC3 rearrangements
Only one PTC was found positive for RET=PTC3, whereas
none of the remaining cases showed either one of the two
rearrangements. The positive case was found in a 21-year-old
male subject with FV PTC and T1b tumor stage (1.2 cm). To
sum up, RET=PTC rearrangement was detected in 50% of FV
PTC (in 6% of total PTC), whereas there was no positive
adenoma, goiter, or HT.
In our series, therefore, BRAF mutation and RET=PTC
rearrangements would seem to be alternative events in the
pathogenesis of PTC.
Discussion
A major problem related to the FNAB technique is that ap-
proximately20%of thebiopsiesyield suspicious=indeterminate
cytological findings which are unable to distinguish benign
from malignant thyroid lesions (27). Consequently, surgery
is generally required in these patients, even though surgical
FIG. 1. (A) Representative image of fine-needle aspiration biopsy of a thyroid high-risk nodule (diameter¼ 14mm); (B)
cytological diagnosis of papillary thyroid carcinoma (PTC); (C) typical image of the laser pressure catapulting process
involving a representative example of PTC tissue placed on a slide after the addition of 1 mL of mineral oil: (i) improvement of
tissue visibility after the addition of oil on the slide, (ii) cutting and catapulting of the PTC, (iii) catapulted PTC on the Eppen-
dorf cap; (D) PTC with BRAFV600E mutation.
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pathology shows cancer in only 20% of them (19). In this light,
for patients with thyroid nodules and cytologically indeter-
minate findings, preoperative detection of specific molecular
markers, such as the PTC-specific BRAFmutation or RET=PTC
rearrangements, would be particularly helpful. Several other
molecular markers for thyroid cancer have been proposed for
preoperative diagnosis in FNAB such as p27, DAP4, human
telelomerase reverse transcriptase, thyroid peroxidase, and
galectin-3, but unfortunately reports have presented limited
data because of lack of specificity or sensitivity or both (28–31).
By contrast, BRAF mutation prevalence has recently been re-
ported in 44%, ranging from 28% to 83%, in PTC (18,32). In
these studies, BRAF mutation was most common in tall-cell
PTC, with an average prevalence of 77%, second most com-
mon in CV PTC (60%), and least common in FV PTC (12%). In
the present study, we demonstrate that detection of BRAF
mutation on FNAB specimens can be easily and reliably per-
formed and correctly identifies 69% of PTC, mostly expressed
in conventional rather than in tall-cell variants (no significant
difference was identified among the variants because of the
small number of cases studied).
In our study, we used a real-time allele-specific amplifica-
tion technique and a mutation detection method in order to
perform a preoperative molecular analysis in a series of pa-
tients with thyroid nodules because their high-resolution US
features were suspicious for increased malignancy risk. Fur-
ther, we compared the tumoral BRAF mutation status de-
tected on preoperative cytological specimens with the final
histological characterization of the tumor: BRAF detection in
FNAB was confirmed in their respective histological samples
using both the real-time allele-specific amplification technique
and the colorimetric assay.
In our study, we confirmed that BRAF gene mutation was
specific for PTC (100%), because no benign thyroid disease
with nodules was found to harbor BRAF mutation. Conse-
quently, BRAF mutation revealed the potential to be a specific
molecular marker with relatively good sensitivity for the di-
agnosis of PTC. Other groups have detected BRAF gene muta-
tion in both surgical and cytological samples, but the major
part of this work has been conducted on retrospective stud-
ies (13,15,23,24,32). The ‘‘blind’’ search for BRAF mutation,
therefore, allowed us to identify correctly two further patients
whose cytological diagnosis was not conclusive for PTC.
Among 19 nodules with indeterminate=suspicious cytology,
100% of those who tested positive for BRAF mutation were
PTC in comparison to only 5.3% of nodules tested negative for
BRAF mutation. FNAB-BRAF mutation was, in fact, detected
in 2=3 PTC cases with suspicious=indeterminate FNAB. These
two cases in our study, although the small number, seem to
confirm the potential usefulness of FNAB-BRAF mutation
in those patients with cytologically suspicious=indeterminate
thyroid nodules, according to recent literature data (33–36).
In our cohort of patients, therefore, BRAFV600E mutation
represents a diagnostic adjunctive tool even for the evalua-
tion of thyroid nodules with indeterminate=suspicious cy-
tological findings. The improvement in PTC diagnosis might
influence the choice of treatment; that is, BRAF positivity may
indicate a more appropriate extent of surgical treatment. With
regard to this latter point, we strongly emphasize that in
our series no patient without diagnostic or indeterminate=
suspicious FNAB was surgically treated merely because he
or she was harboring BRAF mutation. However, the search
for FNAB-BRAF mutation has reduced the number of
indeterminate=suspicious FNAB cytology results, leading to
the recovery of 66.7% of PTC.
Unfortunately, although RET=PTC rearrangement repre-
sents the other genetic lesion often present in PTC, in our
study it did not lead to a more refined molecular diagnosis for
PTC. Considering that the prevalence for RET=PTC rearrange-
rangements varies greatly according to different reports, we
found that only 6% of PTC samples were RET=PTC positive,
confirming its usefulness in only one case of PTC-FV (37–39).
In our series, the reason for such a limited presence of
RET=PTC is not clear. It is likely that this is due to the high
presence of BRAF mutation among our PTC cases (unpub-
lished data). On the other hand, the reduced presence of
RET=PTC rearrangements might be due to the late occur-
rence of RET=PTC in a cell within the transformed clone. In
fact, in our study we found no association of PTC with RET=
PTC and BRAF mutations. However, it remains to be as-
certained whether BRAF mutations may be an alternative
tumor-initiating event in PTC and whether tumors with this
genotype carry a less-favorable prognosis (32–34,40–43). In
our limited number of cases, we are not able to confirm this
important point but we can hypothesize that the extension of
these data in different PTC cohorts might address the ques-
tion. At the same time, a larger long-term monitoring of dis-
ease recurrence for PTC patients with BRAF mutation might
provide more definite answers regarding their prognosis.
In conclusion, our data showed that BRAF mutation, more
significantly than RET=PTC rearrangements, can be readily
and reliably detected on thyroid cytological specimens and
has the potential to become a useful and integrative FNAB
tool for the PTC diagnosis.
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